Scientech Research LLC Takes $1.02 Million Position in Eli Lilly and Company $LLY

Key Points

• Scientech Research LLC acquired 1,232 shares of Eli Lilly and Company, valued at approximately $1,018,000, in the first quarter.
• Institutional investors own 82.53% of Eli Lilly's stock, with significant increases in holdings reported by PNC Financial Services Group and GAMMA Investing LLC in the same quarter.
• Eli Lilly's recent quarterly earnings surpassed expectations with an EPS of $6.31 and revenue of $15.56 billion, marking a 37.6% year-over-year increase in revenue.

Scientech Research LLC purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,232 shares of the company's stock, valued at approximately $1,018,000.

Several other hedge funds have also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC boosted its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company during the first quarter valued at $27,000. Citizens National Bank Trust Department lifted its stake in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in Eli Lilly and Company in the first quarter valued at about $40,000. Finally, Mascagni Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $43,000. Institutional investors own 82.53% of the company's stock.

Insider Activity

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the subject of several recent analyst reports. Cantor Fitzgerald cut their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th. UBS Group lowered their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Wall Street Zen upgraded Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Finally, HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their target price for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Trading Up 1.5%

LLY traded up $11.35 during midday trading on Tuesday, reaching $749.99. 2,983,536 shares of the company's stock traded hands, compared to its average volume of 4,135,773. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $942.35. The stock has a market capitalization of $709.83 billion, a price-to-earnings ratio of 49.02, a P/E/G ratio of 1.01 and a beta of 0.47. The firm has a fifty day moving average of $743.02 and a two-hundred day moving average of $779.63. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business posted $3.92 EPS. The company's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.